BUZZ-Intellipharmaceutics International Inc: FDA cancels conditions on generic drug
** Canadian generic drug maker's U.S.-listed shares up 29.9 pct at $3.69
** Company said late on Wednesday that U.S. FDA canceled several conditions imposed on tentative approval for Focalin, its generic drug for attention deficit hyperactivity disorder
** FDA approved drug tentatively in November 2013 but later indicated company needs to meet certain guidelines before getting final nod
** Maxim Group raises PT to $8 from $7; median PT is $8
** More than 646,000 shares traded as of 12:44 p.m. ET, over 4 times stock's 25-day average volume
** Up to Wednesday's close, stock had risen 26 pct this year
© Thomson Reuters 2017 All rights reserved.